Stella Lee, AAAAI 2021: Current Therapies for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

We were delighted to talk to Dr Stella Lee (University of Pittsburgh, Pittsburgh, PA, US) around the current and future treatment options for chronic rhinosinusitis with nasal polyps. Questions What is the impact of chronic rhinosinusitis with nasal polyps on quality of life, and what are the limitations of current therapies? (0:18) What biologics are […]

Whitney Stevens, AAAAI 2021: Treatment of Aspirin-Exacerbated Respiratory Disease (AERD)

It was a pleasure to speak with Professor Whitney Stevens (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around aspirin desensitisation in aspirin-exacerbated respiratory disease. ‘Aspirin desensitization for AERD in 2020: An update from the AERD work group.’ was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March […]

William Anderson, AAAAI 2021: Adherence to Controller Medication in Paediatric Patients With Asthma

TouchRESPIRATORY got the opportunity to catch up with William Anderson (University of Colorado/Children’s Hospital Colorado, Anschutz Medical Campus, Aurora, CO, US) around his study on adherence to controller medication in paediatric patients with asthma. The abstract ‘Objective controller medication adherence patterns in pediatric patients with asthma in a high-risk multidisciplinary asthma clinic.‘ (ABSTRACT NUMBER: L3) was […]

Alyn Morice, AAAAI 2021: Results from COUGH-1 and COUGH-2

TouchRESPIRATORY got the opportunity to catch up with Alyn Morice (University of Hull, Castle Hill Hospital, Yorkshire, UK) around the unmet needs and treatment of patients with chronic cough (Clinical Trial Identifier: NCT03449134 & NCT03449147). The abstract ‘Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of […]

Dupilumab—A Potential New Biologic for Chronic Rhinosinusitis with Nasal Polyps

US Respiratory & Pulmonary Diseases. 2020;5(1):15-7 DOI: https://doi.org/10.17925/USPRD.2020.5.1.15

Chronic rhinosinusitis (CRS) is a clinical syndrome defined by symptomatic inflammation of the paranasal sinuses and nasal cavity for at least 12 weeks in duration. Historically, CRS has been classified into 2 subgroups, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Those with CRSwNP have a more significant burden of disease and poor […]

Nintedanib—A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease

US Respiratory and Pulmonary Diseases. 2020;5(1):28-32 DOI: https://doi.org/10.17925/USPRD.2020.5.1.28

Systemic sclerosis (SSc) is an autoimmune disorder characterized by inflammation and fibrosis of the skin and other organs. It has a range of clinical manifestations, and the typical internal organs involved include the lungs, kidneys, heart, and gastrointestinal tract. Though it is an uncommon condition, the mortality rate of this disease is higher than any […]

Evidence and E-cigarettes – The English Perspective

European Respiratory & Pulmonary Diseases. 2019;5(1):10–11

Recently, there has been much media coverage on the topic of e-cigarettes. Approaches to new data suggesting that e-cigarettes may be harmful have differed between countries. In particular, the attitude of public health bodies in England has differed significantly from those in other countries internationally. American electronic cigarette company Juul has been accused of deliberately […]

Elexacaftor-tezacaftor-ivacaftor—A Combination Therapy for Phe508del Cystic Fibrosis

US Respiratory & Pulmonary Diseases. 2019;4(1):15–9

Cystic fibrosis (CF), an inherited disease affecting all races and ethnicities, results from defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which leads to dysregulations in the ion and fluid balance across epithelial membranes throughout the body.1–3 The CFTR protein is an anion channel that functions as a transmembrane traffic ATPase which is […]